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Abstract
Background: Contrast-induced nephropathy (CIN) remains to be a potentially serious complication of 
radiographic procedures and is the third leading cause of the acute kidney injury (AKI) among hospital-
ized patients. This clinical trial was performed to assess the preventive effect of oral nicorandil on CIN 
in high-risk patients undergoing cardiac catheterization.
Methods: In this prospective, randomized, controlled trial, 128 patients with at least two risk fac-
tors for CIN undergoing elective percutaneous coronary intervention (PCI) were randomly assigned 
to either the nicorandil group or the control group. Patients in the nicorandil group (n = 64) received 
10 mg nicorandil, daily from 30 min before and up to 3 days after procedure and intravenous hydration 
for 2 h before and 6 h after the procedure, whereas patients in the control group (n = 64) just received 
intravenous hydration. Serum creatinine (SCr) was measured before contrast exposure and at 72 h. 
CIN was defined as an increase of 25% in SCr or > 0.5 mg/dL 72 h after contrast administration.
Results: Contrast-induced nephropathy occurred in 14 out of 64 (21.9%) patients in the control group 
and in 3 out of 64 (4.7%) patients in the nicorandil group. There was a significant difference in the in-
cidence of CIN between the two groups at 72 h after administering the radiocontrast agent (p = 0.008). 
Moreover, there were significant differences between the two groups in SCr and estimated glomerular 
filtration rate 72 h after radiocontrast administration (p < 0.05).
Conclusions: The findings revealed that oral nicorandil had substantial efficacy over hydration pro-
tocol for the development of CIN in high-risk patients undergoing cardiac catheterization. (Cardiol J 
2017; 24, 5: 502–507)
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Introduction
Contrast-induced nephropathy (CIN), also 
known as contrast-induced acute kidney injury 
(CI-AKI) is a well-known, prevalent and serious 
side effect of the administration of iodine contrast 
medium after angiocardiography or radiological 
procedures [1, 2]. In clinical studies, CIN is defined 
as an elevation of serum creatinine level 44.2 µmol/L 
(0.5 mg/dL) or 25% above the baseline within 
48–72 h after contrast administration without an 
alternative cause [3–5]. The exact pathophysiologi-
cal mechanisms of CIN are complex and remain 
unclear. CIN incidence is increasing, ranging from 
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2% in the general population to 50% in high-risk 
patients with conditions like chronic renal impair-
ment or having certain risk factors [2, 3, 6]. The 
most critical risk factors for CIN include diabetes 
mellitus (which is associated with increased risk 
even in patients with preserved renal function), 
congestive heart failure (CHF), age > 75, hyper-
tension, hypotension, decreased renal perfusion, 
female gender, high-osmolar contrast, contrast 
volume, urgent vs. planned PCI and most impor-
tantly, chronic kidney disease (CKD) [7, 8]. CIN is 
the third leading cause of acute kidney injury (AKI) 
in hospitalized patients, accounting for more than 
10% of all renal failure patients and is also associated 
with increased risk of CKD progression and dialysis, 
increased health care costs, increased morbidity and 
mortality [3, 9, 10]. Therefore, preventive measures 
for CIN are inevitable and remains a challenge 
among cardiologists and radiologists.
Nicorandil is a K-ATP channel agonist and 
nitric oxide (NO) donor that have been used to 
treat angina and heart failure. Recent studies re-
vealed that nicorandil may protect the kidney from 
ischemic injury associated with the use of contrast 
media by ameliorating ischemic preconditioning 
[11–13]. Nevertheless, few studies show the ef-
fects of nicorandil in CIN. In the present study, 
it was sought to demonstrate the efficacy of oral 
administration of nicorandil for CIN prevention in 
a prospective, randomized trial in high-risk patients 
undergoing elective PCI.
Methods
The protocol for this study was approved 
by the Ethics Committee of Qom University of 
Medical Sciences (approval number: IR.MUQ.
REC.1394.134), and the written informed consent 
was obtained from all patients before enrollment. 
This study was conducted in accordance with the 
principles of the Declaration of Helsinki.
Study population
This study was a prospective, open-label, 
randomized controlled trial. All adult (> 18 years) 
patients scheduled for PCI were screened for inclu-
sion and exclusion criteria. The inclusion criteria 
were the existence of at least two of the following 
CIN risk factors (at least moderate risk for CIN as 
defined by Mehran risk score) [14]: systolic heart 
failure (with documented ejection fraction < 40%), 
hypertension and diabetes mellitus (noted in their 
past medical history), age > 75 years and renal 
insufficiency (estimated glomerular filtration rate 
[eGFR] < 60 mL/min/1.73 m2, or baseline serum 
creatinine [SCr] > 1.5 mg/dL). The exclusion 
criteria included: end-stage renal insufficiency 
(eGFR < 15 mL/min), acute renal insufficiency, 
pregnancy and lactation, pulmonary edema, car-
diogenic shock, multiple myeloma, history of an 
allergic reaction to contrast agents or nicorandil, 
contrast media exposure within 7 days before the 
procedure, uremia, renal failure which led to hav-
ing dialysis, and the administration of N-acetyl 
cysteine (NAC), metformin, dopamine, theophyl-
line, sodium bicarbonate, mannitol, fenoldopam, 
diuretics, and nephrotoxic medicines within 48 h 
before the procedure.
Each patient randomly received an individual 
number which accordingly divided them into two 
groups; odd numbered patients were assigned to 
group 1 (nicorandil group) and even numbered to 
group 2 (control group).
Study protocol
A total of 128 eligible patients were randomly 
assigned to either the nicorandil group (n = 64) or 
the control group (n = 64), using a balanced block 
randomization method. Patients in the nicorandil 
group received 10 mg nicorandil, daily from 30 min 
before to 3 days after the procedure and standard 
intravenous hydration (1 mL/kg/h) via normal 
saline, a maximum 100 mL/h for 2 h before and 
6 h after the procedure, whereas patients in the 
control group received intravenous hydration via 
the same method. SCr was measured before con-
trast exposure and at 72 h after it.
Several parameters were analyzed in the 
overall population. The GFR was estimated using 
the Cockcroft-Gault formula, (140 – age) × weight 
[kg]/(SCr × 72) in male patients with adjustment 
for female patients multiplied by 0.85. The kidney 
function was categorized according to the stages 
set by the United States National Kidney Founda-
tion and defined by the eGFR value as follows: 
normal kidney function: GFR ≥ 90 mL/min and 
no proteinuria; mild kidney damage: GFR of 60– 
–89 mL/min, with evidence of kidney damage; 
moderate damage: GFR of 30–59 mL/min; severe 
damage: GFR of 15–29 mL/min; and kidney failure 
(dialysis): GFR < 15 mL/min/1.73 m2.
All the tests were performed in the same 
laboratory with the same methodology. PCIs were 
performed through the femoral artery with the low 
osmolar nonionic contrast agent iohexol (Omni-
paque, GE Healthcare, Cork, Ireland). Echocardio-
graphic evaluations of all patients before exposure 
were also performed.
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Study endpoints
The primary endpoint of the study was the de-
velopment of CIN, which is defined as an increase in 
SCr level at 44.2 µmol/L (0.5 mg/dL) or 25% above 
the baseline within 72 h after contrast medium 
administration without an alternative cause. The 
secondary endpoints were the changes in SCr and 
eGFR within 72 h after contrast agent exposure.
Statistical analysis
According to the study of Markota et al. [15], 
the sample size for the significance level of 0.05, 
with the power of 90% is approximately 64 patients 
in each group. The categorical data were presented 
as number and percentages and the continuous data 
were expressed as means ± standard deviation 
(SD). Comparison of continuous variables were 
analyzed by a Student’s t-test and Paired t-test for 
normally distributed values or the Mann-Whitney U 
test and Wilcoxon rank sum test for non-normally 
distributed values. The categorical variables were 
compared using the c2 test or Fisher’s exact test 
if the expected frequency was < 5. The one-way 
analysis of covariance (ANCOVA) was used for 
comparison of treatment effects between the two 
groups adjusting for baseline values and confound-
ing factors. Statistical significance was defined as 
two-tailed p values less than 0.05. 
Results
The patients’ baseline characteristics are 
presented in Table 1. There were no significant 
differences between the two groups in baseline 
clinical characteristics. 
Before contrast exposure and 72 h there-
after, the changes in SCr and eGFR between 
the two groups were compared (Tables 2, 3). In 
the nicorandil group, the median SCr concentra-
tion insignificantly increased from 1.08 mg/dL to 
1.11 mg/dL at 72 h after radiocontrast administra-
tion (p = 0.088). In the control group, the median 
SCr concentration significantly increased from 
1.03 mg/dL to 1.13 mg/dL at 72 h after radiocon-
trast administration (p < 0.001).
In the nicorandil group, the mean eGFR insig-
nificantly decreased from 76.39 mL/min/1.73 m2 to 
73.96 mL/min/1.73 m2 at 72 h after radiocontrast 
administration (p = 0.067). In the control group, 
the mean eGFR significantly decreased from 
83 mL/min/1.73 m2 to 76.23 mL/min/1.73 m2 at 
72 h after radiocontrast administration (p < 0.001).
Table 1. Baseline clinical and procedural characteristics of the patients.
Variables [mean ± SD or n (%)] Nicorandil group Control group P*
Male 39 (60.9%) 40 (62.5%) 0.856
Age [year] 61.35 ± 11.77 57.64 ± 12.42 0.085
Age > 75 years 10 (15.6%) 8 (12.5%) 0.611
Systemic hypertension 35 (54.7%) 41 (64.1%) 0.280
Diabetes mellitus 27 (42.2%) 26 (40.6%) 0.858
Smoking 22 (36.7%) 13 (31%) 0.550
Hemoglobin 13.51 ± 1.5 14.8 ± 3.6 0.010
Hematocrit 41.35 ± 4.6 42.60 ± 6.1 0.194
Fasting blood sugar 133.62 ± 56.7 132.53 ± 56.1 0.913
Triglyceride 153.92 ± 70 165.59 ± 86.5 0.403
HDL 42.98 ± 10.8 42.31 ± 11 0.730
LDL 91.5 ± 38.1 100.98 ± 42.4 0.186
BMI [kg/m2] 28.43 ± 5.6 27.78 ± 4.8 0.484
LVEF [%] 48.87 ± 6.8 49.14 ± 5.8 0.812
LVEF < 40 [%] 9 (14.5%) 11 (17.2%) 0.682
GFR < 60 [mL/min/1.73 m2] 19 (29.7%) 13 (20.3%) 0.221
Dose of contrast agent [mL] 213.98 ± 44.6 202.26 ± 44.4 0.139
*Between-group comparisons were assessed using independent samples t-test for the normally distributed value or the Mann-Whitney U for 
non-normally distributed values. The categorical variables were compared through using Pearson chi-square test; HDL — high-density lipo-
protein; LDL — low-density lipoprotein; BMI — body mass index; LVEF — left ventricular ejection fraction; GFR — glomerular filtration rate
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CIN occurred in 14 out of 64 (21.9%) pa-
tients in the control group and in 3 out of 64 
(4.7%) patients in the nicorandil group. There was 
a significant difference in the incidence of CIN 
between the two groups at 72 h after administer-
ing the radiocontrast agent. The odds of CIN in 
the control group were 5.69 times higher than the 
intervention group (p = 0.008, CI 95% for OR = 
= 1.54, 20.92) (Fig. 1).
Discussion
In this study, the efficacy of oral nicorandil for 
the prevention from CIN was evaluated. 
According to the available research, this study 
has shown for the second time that prophylactic 
oral administration of nicorandil had significant 
reduction in CIN incidence in high risk populations 
for the development of CIN. In addition, the main 
finding of the present study was that the use of 
low-dose oral nicorandil reduced CIN as well as 
having fewer side effects. In general, few studies 
have focused on the preventive effects of nicorandil 
on CIN. In the study by Ko et al. [12], 81 patients 
with an eGFR < 60 mL/min received nicorandil 
12 mg intravenously for 30 min prior to coronary 
angiography. This study showed that prophylactic 
intravenous infusion of nicorandil did not decrease 
the incidence of CIN in patients with renal dys-
function undergoing coronary angiography [11]. In 
another study by Fan et al. [13], 120 patients with 
an eGFR of 60 mL/min or less who were undergo-
ing elective cardiac catheterization received nico-
randil 10 mg orally, three times daily from 2 days 
before to 3 days after the procedure. In that study, 
the incidence of CIN at 48 h after procedure was 
significantly lower in nicorandil group compared 
to the control group. This was in accordance with 
the present study that oral nicorandil decreases the 
incidence of CIN in high-risk patients undergoing 
elective cardiac catheterization. Various pharma-
cologic and therapeutic interventions have been 
Figure 1. Incidence of contrast-induced nephropathy 
(CIN) is significantly lower in the nicorandil group (n = 64) 
compared to the control group (n = 64); p = 0.008.
Table 2. Biochemical and renal function changes before and 72 h after contrast medium exposure.
Groups Measurement Baseline After intervention P*
Serum creatinine [mg/dL] Nicorandil group 1.0859 ± 0.22 1.1125 ± 0.19 0.088
Saline group 1.0359 ± 0.15 1.1344 ± 0.18 < 0.001 
eGFR [mL/min/1.73 m2] Nicorandil group 76.39 ± 24.6 73.96 ± 23.3 0.067
Saline group 83 ± 28.1 76.23 ± 26.3 < 0.001
*Within-group comparisons were assessed using Paired t-test for normally distributed value or the Wilcoxon rank sum test for non-normally 
distributed values; eGFR — estimated glomerular filtration rate
Table 3. Results of ANCOVA adjusting for age and baseline values of dependent variables.
Group MD* SE* 95% CI for MD Effect 
size
Power P*
SCr (nicorandil vs. normal saline) –0.059 0.022 –0.103 –0.015 0.254 0.802 0.009
eGFR (nicorandil vs. normal saline) 3.96 1.72 0.55 7.38 0.206 0.627 0.023
CI — confidence interval; eGFR — estimated glomerular filtration rate; MD — mean differences after intervention between two group; SCr — 
serum creatinine; SE — standard error of mean; p — obtained from ANCOVA after adjusting for age and baseline values of dependent variables
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applied to decrease the occurrence of CIN including 
NAC, theophylline, calcium antagonists, diuretics, 
ascorbic acid, statins, sodium bicarbonate, adeno-
sine antagonists, fenoldopam, atrial natriuretic 
peptide and other agents [3, 8]. Among them, NAC 
has been of considerable interest and several clini-
cal studies and meta-analyses have been performed 
to assess the efficacy of NAC in the prevention of 
CIN. However, the NAC results have also been 
controversial and the optimal therapeutics remain 
unclear [1, 16, 17]. Currently, peri-procedural in-
travenous hydration, using iso-osmolar and/or low-
osmolar contrast agents instead of high-osmolar 
agents and limiting the dose of contrast media are 
the confirmed strategies against CIN [18, 19]. In 
this study, Iohexol (low-osmolar, non-ionic contrast 
medium) was also used to reduce complications 
and CIN incidence. 
Although, the exact pathophysiology of CIN 
remains unclear, the possible direct and indirect 
pathophysiologic effects of contrast exposure that 
have been suggested include renal vasoconstric-
tion, which leads to decreased oxygenation of the 
medulla causing ischemia and renal injury, direct 
tubular toxicity due to the creation of oxygen free 
radicals, causing acute tubular necrosis, and a de-
crease in glomerular filtration due to the alterations 
of tubulo-glumeral regulatory mechanisms [4, 8, 
20, 21]. Nicorandil, a K-ATP channel opener and 
a NO donor, is currently used in the treatment 
of angina and acute heart failure. Recent studies 
showed that activation of the K-ATP channel ame-
liorate ischemia-reperfusion in the kidney by pre-
venting accumulation of reactive oxygen radicals 
(ROS) in mitochondria. In addition, these findings 
revealed that nicorandil might protect the kidney 
from the ischemic injury associated with the use 
of contrast media by inducing NO production and 
suppressing synthesis of endothelin-1 [11–13]. 
However, the exact mechanisms of the effect of 
nicorandil on CIN are unknown and further studies 
are required to assess the exact mechanism.
Limitations of the study
This study was faced with a series of limi-
tations. First, the main limitation of the pres-
ent study was that it was not a multi-centered, 
a double-blind study which may contain an observer 
bias requires verification. Second, the creatinine 
clearance was computed using the Cockcroft–Gault 
formula, rather than a direct measurement. Third, 
the sample size was small. A larger multi-centered, 
double-blind, and randomized trial including oth-
er clinical settings are required to confirm the 
beneficial effects of nicorandil on preventing CIN. 
Furthermore, this study is restricted by the lack of 
independent cost engineering committee (CEC).
The present findings revealed that oral nico-
randil had substantial efficacy over hydration 
protocol in high-risk patients for the development 
of CIN. It is therefore concluded that the use of 
nicorandil could be effective in prevention of CIN; 
however, further controlled clinical studies are 
needed to resolve the uncertainties concerning 
the relative effectiveness of nicorandil in CIN 
prevention. 
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